Differentiation dependent expression of urocortin's mRNA and peptide in human osteoprogenitor cells: Influence of BMP-2,TGF-beta-1 and dexamethasone

Journal of Molecular Histology

Volumn 40, Issue 5-6, 2009, Pages 331-341

  Tezval, Mohammad ^a   Tezval, Hossein ^b   Dresing, Klaus ^a   Stuermer, Ewa Klara ^a   Blaschke, Martina ^a   Stuermer, Klaus Michael ^a   Siggelkow, Heide ^a,c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c University Medicine Goettingen ^*  (Germany)

Author keywords

CRF related peptide; Growth factors; Osteoprogenitor cells; Urocortin

Indexed keywords

ASCORBIC ACID; BONE MORPHOGENETIC PROTEIN 2; CALCITRIOL; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; DEXAMETHASONE; GLYCEROL 2 PHOSPHATE; LYMPHOTOXIN; MESSENGER RNA; OSTEOCALCIN; PEPTIDE; TRANSFORMING GROWTH FACTOR BETA1; UROCORTIN;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL; METABOLIC BONE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ADULT; AGED; BONE DISEASES, METABOLIC; BONE MORPHOGENETIC PROTEIN 2; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELLS, CULTURED; DEXAMETHASONE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; ORGAN SPECIFICITY; OSTEOBLASTS; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; UROCORTINS;

EID: 77951023405     PISSN: 15672379     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10735-009-9244-z     Document Type: Article

References (34)

1. Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson KL, Vale WW, Lee KF (2002) Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 99:7734-7739
2. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL (2004) The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 101:3697-3702
3. Bamberger CM, Minas V, Bamberger AM, Charalampopoulos I, Fragouli Y, Schulte HM, Makrigiannakis A (2007) Expression of urocortin in the extravillous human trophoblast at the implantation site. Placenta 28:127-132
4. Boorse GC, Denver RJ (2006) Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen Comp Endocrinol 146:9-18
5. Bouxsein ML, Devlin MJ, Glatt V, Dhillon H, Pierroz DD, Ferrari SL (2009) Mice lacking beta-adrenergic receptors have increased bone mass but are not protected from deleterious skeletal effects of ovariectomy. Endocrinology 150:144-152
6. Caetano-Lopes J, Canhao H, Fonseca JE (2007) Osteoblasts and bone formation. Acta Reumatol Port 32:103-110
7. Carlson KW, Nawy SS, Wei ET, Sadee W, Filov VA, Rezsova VV, Slominski A, Quillan JM (2001) Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res 21:1173-1179
8. Fekete EM, Zorrilla EP (2007) Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28:1-27
9. Fekete C, Sarkar S, Rand WM, Harney JW, Emerson CH, Bianco AC, Beck-Sickinger A, Lechan RM (2002) Neuropeptide Y1 and Y5 receptors mediate the effects of neuropeptide Y on the hypothalamic-pituitary-thyroid axis. Endocrinology 143: 4513-4519
10. Hinkle RT, Donnelly E, Cody DB, Bauer MB, Sheldon RJ, Isfort RJ (2004) Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force. J Muscle Res Cell Motil 25:539-547
11. Hughes FJ, Turner W, Belibasakis G, Martuscelli G (2006) Effects of growth factors and cytokines on osteoblast differentiation. Periodontology 2000 41:48-72
12. Ikeda K, Tojo K, Oki Y, Nakao K (2002) Urocortin has cellproliferative effects on cardiac non-myocytes. Life Sci 71: 1929-1938
13. Isfort RJ, Wang F, Tscheiner M, Donnelly E, Bauer MB, Lefever F, Hinkle RT, Mazur AW (2005) Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy. J Med Chem 48:262-265
14. Kageyama K, Hanada K, Nigawara T, Moriyama T, Terui K, Sakihara S, Suda T (2006) Urocortin induces interleukin-6 gene expression via cyclooxygenase-2 activity in aortic smooth muscle cells. Endocrinology 147:4454-4462
15. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, Ebina M, Nukiwa T, Sasano H (2002) Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 87:340-346
16. Kotz CM, Wang C, Levine AS, Billington CJ (2002) Urocortin in the hypothalamic PVN increases leptin and affects uncoupling proteins-1 and -3 in rats. Am J Physiol Regul Integr Comp Physiol 282:R546-R551
17. Latchman DS (2002) Urocortin. Int J Biochem Cell Biol 34:907-910
18. Marie PJ, Sabbagh A, de Vernejoul MC, Lomri A (1989) Osteocalcin and deoxyribonucleic acid synthesis in vitro and histomorphometric indices of bone formation in postmenopausal osteoporosis. J Clin Endocrinol Metab 69:272-279
19. Marie PJ, Hott M, Launay JM, Graulet AM, Gueris J (1993) In vitro production of cytokines by bone surface-derived osteoblastic cells in normal and osteoporotic postmenopausal women: relationship with cell proliferation. J Clin Endocrinol Metab 77:824-830
20. Nazarloo HP, Buttrick PM, Saadat H, Dunn AJ (2006) The roles of corticotropin-releasing factor-related peptides and their receptors in the cardiovascular system. Curr Protein Pept Sci 7:229-239
21. Owen TA, Aronow M, Shalhoub V, Barone LM, Wilming L, Tassinari MS, Kennedy MB, Pockwinse S, Lian JB, Stein GS (1990) Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol 143:420-430
22. Ponce ML, Koelling S, Kluever A, Heinemann DE, Miosge N, Wulf G, Frosch KH, Schutze N, Hufner M, Siggelkow H (2008) Coexpression of osteogenic and adipogenic differentiation markers in selected subpopulations of primary human mesenchymal progenitor cells. J Cell Biochem 104:1342-1355
23. Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I (1994) Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev Biol 161:218-228
24. Sehringer B, Zahradnik HP, Simon M, Ziegler R, Noethling C, Schaefer WR (2004) mRNA expression profiles for corticotrophin-releasing hormone, urocortin, CRH-binding protein and CRH receptors in human term gestational tissues determined by real-time quantitative RT-PCR. J Mol Endocrinol 32:339-348
25. Siggelkow H, Rebenstorff K, Kurre W, Niedhart C, Engel I, Schulz H, Atkinson MJ, Hufner M (1999) Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem 75:22-35
26. Siggelkow H, Eidner T, Lehmann G, Viereck V, Raddatz D, Munzel U, Hein G, Hufner M (2003) Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res 18:529-538
27. Siggelkow H, Schmidt E, Hennies B, Hufner M (2004) Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts. Bone 35:570-576
28. Slominski A, Wortsman J (2000) Neuroendocrinology of the skin. Endocr Rev 21:457-487
29. Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kauser S, Wortsman J, Tobin DJ (2006) Corticotropin releasing hormone and the skin. Front Biosci 11:2230-2248
30. Tezval H, Jurk S, Atschekzei F, Becker JU, Jahn O, Serth J, Kuczyk MA (2009a) Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation. World J Urol 27(6):825-830
31. Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA, Merseburger AS (2009b) The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate 69(4):443-448
32. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C et al (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287-292
33. Viereck V, Siggelkow H, Tauber S, Raddatz D, Schutze N, Hufner M (2002) Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts. J Cell Biochem 86:348-356
34. Xing L, Boyce BF (2005) Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 328: 709-720